Lundbeck's hopes have high costs: "You won't see us reaching that level in the future"

Pharmaceutical company Lundbeck has upgraded its R&D expenses due to high stakes on migraine drug Vyepti. The level is unnaturally high but will fluctuate in the future, says head of R&D.
Photo: Jens Dresling
Photo: Jens Dresling
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

In the last year, Denmark's second-largest pharmaceutical company, Lundbeck, has upgraded its expenses for research and development, not least due to its major stakes on turning migraine drug Vyepti into a blockbuster.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading